Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 27, 2026
Jointly reported with Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-04-23 · Other · Disposed 12,929,322 · Balance 0 F1: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F2: The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. |
| Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 827,586 · Balance 0 F1: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F3: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%. F2: The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash.
F2: The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
F3: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 27, 2026 21:27 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerPre-Funded Warrant (right to buy) · Derivative | 827,586 | $21.50 Strike: $0.00 | $17,793,016.24 |
DisclosureSEC source: 0001193125-26-182440 · ownership.xml · derivative · entry 2 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 827,586 shares Expires not disclosed F1 · kind: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F1 · shares: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F3 · derivative.exercise_date: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%. F3 · derivative.expiration_date: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:27 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 12,929,322 | $21.50 | $277,980,423.00 |
DisclosureSEC source: 0001193125-26-182440 · ownership.xml · nonDerivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F1 · shares: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseWarrant (right to buy) · Derivative | 827,586 | $14.50 Strike: $0.00 | $11,999,914.24 |
DisclosureSEC source: 0000950170-24-090703 · ownership.xml · derivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,586 Underlying: Common Stock · 827,586 shares Expires not disclosed F1 · derivative.exercise_date: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%. F1 · derivative.expiration_date: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| October 20, 2023 Filed Oct 20, 2023 20:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 111,387 | $9.97 | $1,110,907.11 |
DisclosureSEC source: 0001209191-23-053235 · doc4.xml · nonDerivative · entry 3 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,929,322 F4 · price: The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.83 to $10.13 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 20:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 384,400 | $10.06 | $3,867,371.52 |
DisclosureSEC source: 0001209191-23-053235 · doc4.xml · nonDerivative · entry 2 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,817,935 F3 · price: The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.88 to $10.20 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 979,667 | $10.21 | $10,000,048.87 |
DisclosureSEC source: 0001209191-23-053235 · doc4.xml · nonDerivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,433,535 F1 · price: The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $10.07 to $10.29 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 769,230 | $13.00 | $9,999,990.00 |
DisclosureSEC source: 0001209191-23-036242 · doc4.xml · nonDerivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,453,868 F1 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 1,200,000 | $15.00 | $18,000,000.00 |
DisclosureSEC source: 0001209191-22-038431 · doc4.xml · nonDerivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,684,638 F1 · shares: Represents securities purchased in the Issuer's public offering. F2 · ownership.direct: The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 23:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 4,615 | $14.73 | $67,975.72 |
DisclosureSEC source: 0001209191-22-004174 · doc4.xml · nonDerivative · entry 3 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,484,638 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 23:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 58,818 | $14.70 | $864,565.78 |
DisclosureSEC source: 0001209191-22-004174 · doc4.xml · nonDerivative · entry 2 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,480,023 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.75, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 23:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 43,429 | $14.26 | $619,367.03 |
DisclosureSEC source: 0001209191-22-004174 · doc4.xml · nonDerivative · entry 1 AI Day1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,421,205 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.53, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 741,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037697 · doc4.xml · derivative · entry 4 AI Day 1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 741,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of common stock of the Issuer immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of common stock of the Issuer immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of common stock of the Issuer immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F3 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 7,761,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037697 · doc4.xml · derivative · entry 3 AI Day 1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,761,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock automatically converted into one share of common stock of Day One Biopharmaceuticals, Inc. (the "Issuer") immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock automatically converted into one share of common stock of Day One Biopharmaceuticals, Inc. (the "Issuer") immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock automatically converted into one share of common stock of Day One Biopharmaceuticals, Inc. (the "Issuer") immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F3 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 875,000 | $16.00 | $14,000,000.00 |
DisclosureSEC source: 0001209191-21-037697 · doc4.xml · nonDerivative · entry 2 AI Day 1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,377,776 F4 · kind: Represents securities purchased in the Issuer's initial public offering. F3 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionCommon Stock | 8,502,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037697 · doc4.xml · nonDerivative · entry 1 AI Day 1 LLC · CIK 0001863302 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,502,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Redeemable Convertible Preferred Stock automatically converted into one share of common stock of Day One Biopharmaceuticals, Inc. (the "Issuer") immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F2 · price: Each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of common stock of the Issuer immediately prior to the completion of the Issuer's initial public offering and had no expiration date. F3 · ownership.direct: The securities reported are held directly by AI Day 1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day 1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.